Compare · RMD vs STVN
RMD vs STVN
Side-by-side comparison of ResMed Inc. (RMD) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.69B, about 7.8x STVN ($4.31B).
- Over the past year, RMD is down 2.0% and STVN is down 28.2% - RMD leads by 26.2 points.
- RMD has been more active in the news (13 items in the past 4 weeks vs 10 for STVN).
- Both have 25 recent analyst ratings on file.
- Company
- ResMed Inc.
- Stevanato Group S.p.A.
- Price
- -
- -
- Market cap
- $33.69B
- $4.31B
- 1M return
- -1.16%
- -17.88%
- 1Y return
- -2.01%
- -28.21%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 10
- Recent ratings
- 25
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest RMD
- Chairman and CEO Farrell Michael J. covered exercise/tax liability with 8,111 units of ResMed Common Stock, decreasing direct ownership by 2% to 471,774 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Bloomer Aaron covered exercise/tax liability with 1,095 units of ResMed Common Stock, decreasing direct ownership by 12% to 7,977 units (SEC Form 4) to satisfy withholding tax
- Director Farrell Peter C covered exercise/tax liability with 169 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 51,634 units (SEC Form 4) (withholding obligation)
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
Latest STVN
- Director Federici William J bought $274,400 worth of Ordinary Shares (20,000 units at $13.72), increasing direct ownership by 74% to 46,991 units (SEC Form 4)
- SEC Form 6-K filed by Stevanato Group S.p.A.
- Director Morel Donald E Jr bought $326,750 worth of Ordinary Shares (25,000 units at $13.07), increasing direct ownership by 67% to 62,424 units (SEC Form 4)
- Stevanato Group S.p.A. downgraded by William Blair
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
- Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
- Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
- Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026